Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
F 43.99 0.66% 0.29
BMY closed up 0.66 percent on Friday, May 3, 2024, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 7
*** please verify all earnings dates ***
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.66%
New 52 Week Low Weakness 0.66%
Oversold Stochastic Weakness 0.66%
Spinning Top Other -0.50%
Calm After Storm Range Contraction -0.50%
New 52 Week Low Weakness -0.50%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bristol-Myers Squibb Company Description

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Diabetes Cancer Treatment Clinic Pharmaceutical Products Hypertension Melanoma Schizophrenia Hepatitis B Rheumatoid Arthritis Stroke Multiple Myeloma Dystrophy Epidermal Growth Factor Receptor Depressive Disorder Hepatitis C Immunodeficiency Hepatitis C Virus Organic Chemistry Diabetic Nephropathy Hepatitis B Virus Atrial Fibrillation Interferon Biopharmaceutical Products Treatment Of Diabetes Chronic Myeloid Leukemia Heart Attack Hepatitis C Virus Infection Metastatic Melanoma Transplant Rejection Treatment Of Hypertension Kidney Transplant Leptin Lipodystrophy

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 66.2547
52 Week Low 43.333
Average Volume 16,117,954
200-Day Moving Average 52.57
50-Day Moving Average 49.98
20-Day Moving Average 47.46
10-Day Moving Average 45.70
Average True Range 1.02
RSI (14) 25.93
ADX 37.81
+DI 10.02
-DI 40.61
Chandelier Exit (Long, 3 ATRs) 49.04
Chandelier Exit (Short, 3 ATRs) 46.38
Upper Bollinger Bands 52.47
Lower Bollinger Band 42.46
Percent B (%b) 0.15
BandWidth 21.09
MACD Line -1.82
MACD Signal Line -1.41
MACD Histogram -0.4139
Fundamentals Value
Market Cap 89.51 Billion
Num Shares 2.03 Billion
EPS 3.86
Price-to-Earnings (P/E) Ratio 11.40
Price-to-Sales 2.25
Price-to-Book 4.49
PEG Ratio 0.67
Dividend 2.31
Dividend Yield 5.25%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.96
Resistance 3 (R3) 44.96 44.65 44.80
Resistance 2 (R2) 44.65 44.40 44.64 44.74
Resistance 1 (R1) 44.32 44.25 44.48 44.31 44.69
Pivot Point 44.00 44.00 44.08 44.00 44.00
Support 1 (S1) 43.67 43.76 43.84 43.67 43.29
Support 2 (S2) 43.36 43.60 43.35 43.24
Support 3 (S3) 43.03 43.36 43.18
Support 4 (S4) 43.02